Mama

Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dra. Noémia Afonso	Recrutamento	2017-002821-39
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Ana Ferreira	Recrutamento	2017-002821-39

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar do Porto Largo do Prof. Abel Salazar 4099-001, Porto - Portugal	Dra. Noémia Afonso	Recrutamento	2017-004869-27
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Marta Ferreira	Recrutamento	2017-004869-27
Centro Hospitalar Universitário Lisboa Norte Hospital de Santa Maria Av. Prof. Egas Moniz 1649-035 Lisboa - Portugal	Dra. Leonor Ribeiro	Recrutamento	2017-004869-27
Fundação Champalimaud Avenida Brasília 1400-038 Lisboa - Portugal	Dra. Fátima Cardoso	Recrutamento	2017-004869-27

A randomized, multicenter, open-label cross-over study to evaluate patient preference and satisfaction of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in patients with HER2-positive early breast cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Susana Sousa	Recrutamento	2018-002153-30

Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar Universitário do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dra. Noémia Afonso	Recrutamento	2017-003131-11
Centro Hospitalar de Vila Nova de Gaia/Espinho Rua Conceição Fernandes, s/n 4434-502 Vila Nova de Gaia - Portugal	Dr. António Moreira Pinto	Recrutamento	2017-003131-11
Fundação Champalimaud Av. Brasília 1400-038 Lisboa	Dra. Fátima Cardoso	Recrutamento	2017-003131-11
Hospital de Braga Sete Fontes - São Victor 4710- 243 Braga - Portugal	Dra. Catarina Portela	Recrutamento	2017-003131-11
Hospital Beatriz Ângelo Avenida Carlos Teixeira, nº 3 2674-514 Loures - Portugal	Prof. Dr. José Luís Passos Coelho	Recrutamento	2017-003131-11
Unidade Local de Saúde de Matosinhos Hospital Pedro Hispano Rua de Dr. Eduardo Torres Senhora da Hora - Portugal	Dra. Matilde Salgado	Recrutamento	2017-003131-11

A Phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus treatment of physician's choice for HER2- low, unresectable and/or metastatic breast cancer subjects

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Senhora da Oliveira Guimarães Rua dos Cutileiro, 114 Creixomil Guimarães - Portugal	Dra. Ilda Faustino	Recrutamento	2018-003069-33
Unidade Local de Matosinhos, EPE Hospital Pedro Hispano Rua Dr. Eduardo Torres 4464-513 Senhora da Hora - Portugal	Dra. Matilde Salgado	Recrutamento	2018-003069-33

Elacestrant Monotherapy for the Treatment of ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active- Controlled, Multicenter Trial

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Senhora da Oliveira Guimarães Rua dos Cutileiro, 114 Creixomil Guimarães - Portugal	Dra. Alexandra Teixeira	Recrutamento	2018-002990-24

An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-La Roche sponsored pertuzumab study

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar Lisboa Norte Hospital de Santa Maria Av. Egas Moniz 1649-028 Lisboa - Portugal	Dr. Luís António Marques Costa	Recrutamento	2014-002048-42

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast Cancer(TNBC) (CAPItello-290)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Senhora da Oliveira Guimarães Rua dos Cutileiro, 114 Creixomil Guimarães - Portugal	Dra. Camila Coutinho	Recrutamento	2018-004687-64

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Luz Av. Lusíada 100 1500-650 Lisboa - Portugal	Dra. Mónica Nave	Recrutamento	2017-000419-17
Hospital Beatriz Ângelo Av. Carlos Teixeira, 3 2674-214 Loures - Portugal	Prof. Dr. José Luís Passos Coelho	Recrutamento	2017-000419-17

Targeting EGFR/ERBB2 with Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer (NEREA trial)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Luz Av. Lusíada 100 1500-650 Lisboa - Portugal	Dra. Catarina Pulido	Recrutamento	2019-000710-11

A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for her2-positive breast cancer at high risk of recurrence following preoperative therapy

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital Beatriz Ângelo Av. Carlos Teixeira, 3 2674-514, Loures - Portugal	Dra. Mafalda Casa-Nova	Recutamento	2020-003681-40

A phase III randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of gdc-9545 combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor-positive, her2-negative locally advanced or metastatic breast cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Luz Av. Lusíada, 100 1500-650, Lisboa - Portugal	Dra. Catarina Pulido	Recrutamento	2020-000119-66

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Luz Av. Lusíada, 100 1500-650, Lisboa - Portugal	Dra. Mónica Nave	Recrutamento	2019-002469-37

A Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan (DS-8201a) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer with Brain Metastases and/or Leptomeningeal Carcinomatosis

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Luz Av. Lusíada, 100 1500-650, Lisboa - Portugal	Dra. Mónica Nave	Recrutamento	2019-001739-29

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy

Contactos de Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar Lisboa Ocidental Av. Prof. Dr. Reinaldo dos Santos, 2790-134 Carnaxide - Portugal	Dra. Ana Martins	Recrutamento	2020-003982-20
Hospital CUF Descobertas Rua Mário Botas (Parque das Nações) 1998-018 Lisboa - Portugal	Dra. Sofia Braga	Recrutamento	2020-003982-20

An open-label, phase IIIib, single arm, multicenter safety study of atezolizumab (tecentriq) plus nabpaclitaxel or paclitaxel in the treatment of unresectable locally advanced or metastatic triple-negative breast cancer

Contatos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar Lisboa Ocidental Av. Prof. Dr. Reinaldo dos Santos, 2790-134 Carnaxide - Portugal	Dra. Ana Martins	Recrutamento	2019-002488-91
Hospital CUF Descobertas Rua Mário Botas (Parque das Nações) 1998-018 Lisboa - Portugal	Dra. Sofia Braga	Recrutamento	2019-002488-91